{
    "root": "5001b104-2557-499d-bf89-0a01149937a9",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "TOUJEO",
    "value": "20250312",
    "ingredients": [
        {
            "name": "insulin glargine",
            "code": "2ZM8CX04RZ",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_145810"
        },
        {
            "name": "zinc",
            "code": "J41CSQ7QDS",
            "drugbank_id": "https://go.drugbank.com/drugs/DB01593"
        },
        {
            "name": "metacresol",
            "code": "GGO4Y809LO"
        },
        {
            "name": "glycerin",
            "code": "PDC6A3C0OX",
            "drugbank_id": "https://go.drugbank.com/drugs/DB09462"
        },
        {
            "name": "water",
            "code": "059QF0KO0R",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_15377"
        },
        {
            "name": "METACRESOL",
            "code": "GGO4Y809LO"
        },
        {
            "name": "GLYCERIN",
            "code": "PDC6A3C0OX",
            "drugbank_id": "https://go.drugbank.com/drugs/DB09462"
        },
        {
            "name": "WATER",
            "code": "059QF0KO0R",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_15377"
        }
    ],
    "indications": {
        "text": "toujeo indicated improve glycemic control adults pediatric patients 6 years age older diabetes mellitus .",
        "doid_entities": [
            {
                "text": "diabetes mellitus (DOID:9351)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_9351"
            }
        ],
        "orphanet_entities": []
    },
    "contraindications": {
        "text": "individualize dose based type diabetes , metabolic needs , blood glucose monitoring results glycemic control goal . ( 2.2 ) administer subcutaneously abdominal area , thigh , deltoid daily time day , time every day . ( 2.1 ) rotate injection sites reduce risk lipodystrophy localized cutaneous amyloidosis . ( 2.1 ) dilute mix insulin solution . ( 2.1 ) full prescribing information recommended starting patients type 2 diabetes switch toujeo insulins ( 2.3 , 2.4 ) closely monitor glucose switching toujeo initial weeks thereafter . ( 2.4 )",
        "doid_entities": [
            {
                "text": "diabetes (DOID:9351)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_9351"
            },
            {
                "text": "lipodystrophy (DOID:811)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_811"
            },
            {
                "text": "amyloidosis (DOID:9120)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_9120"
            },
            {
                "text": "type 2 diabetes (DOID:9352)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_9352"
            }
        ],
        "orphanet_entities": []
    },
    "warningsAndPrecautions": null,
    "adverseReactions": "toujeo contraindicated : episodes hypoglycemia [ ( 5.3 ) ] . patients hypersensitivity insulin glargine excipients toujeo [ ( 5.5 ) ] .",
    "indications_original": "TOUJEO is indicated to improve glycemic control in adults and pediatric patients 6 years of age and older with diabetes mellitus.",
    "contraindications_original": "Individualize dose based on type of diabetes, metabolic needs, blood glucose monitoring results and glycemic control goal. ( 2.2 ) Administer subcutaneously into the abdominal area, thigh, or deltoid once daily at any time during the day, at the same time every day. ( 2.1 ) Rotate injection sites to reduce risk of lipodystrophy and localized cutaneous amyloidosis. ( 2.1 ) Do not dilute or mix with any other insulin or solution. ( 2.1 ) See Full Prescribing Information for the recommended starting dosage in patients with type 2 diabetes and how to switch to TOUJEO from other insulins ( 2.3 , 2.4 ) Closely monitor glucose when switching to TOUJEO and during initial weeks thereafter. ( 2.4 )",
    "adverseReactions_original": "TOUJEO is contraindicated:\n                  \n                     During episodes of hypoglycemia [see Warnings and Precautions (5.3)].\n                     In patients with hypersensitivity to insulin glargine or any excipients in TOUJEO [see Warnings and Precautions (5.5)].",
    "drug": [
        {
            "name": "TOUJEO",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_145810"
        }
    ]
}